In this aspect, previous studies demonstrated the effectiveness of TAK1 inhibition or deficiency in skin cancer [40], multiple lymphoma [41], KRAS-dependent colon cancers [42], breast cancer [37] and cervical cancer [38]. This evidence concerns the gene KRAS and skin neoplasm.